FDA Advisory Committee Approves Peptides Amid Controversy

The advisory committee made a narrow decision to approve several peptides, and the reactions are mixed. Supporters see it as a win for the “Make America Back to Health” movement, while critics worry it might lead to more drug abuse.

The FDA’s Pharmacy Compounding Advisory Committee voted to approve six out of seven peptides that were under review for the 503A bulk list. This list is crucial because it dictates which drugs pharmacies can compound and prescribe. Peptide drugs, composed of short amino acid chains, are primarily given through injections.

Interestingly, peptides have gained attention through social media trends like “biohacking” and “lookmax,” where individuals pursue unconventional methods to alter their health and appearance.

On Thursday, most panel members backed the approval of KPV and TB-500 for wound healing, along with BPC-157 for ulcerative colitis and MOTS-c for obesity in addition to osteoporosis. However, the following day saw a majority oppose emideltide, referring to issues like withdrawal and chronic insomnia.

“I voted yes because it’s time to empower patients, doctors, and pharmacists with these decisions,” stated David Pope, the chief pharmacy officer at Xifin Pharmacy Solutions, right after he voted in favor of BPC-157.

While FDA officials advised against approving the peptide due to insufficient safety and efficacy studies, it’s important to note that the FDA doesn’t have to follow the committee’s recommendations. The agency will soon disclose its decision and open a period for public comments, though it has completed a similar procedure for just ten substances since 1977.

A representative from the U.S. Department of Health and Human Services told the Daily Caller News Foundation that all panel members went through a standard ethics review. Those who didn’t meet the criteria were excluded.

“The FDA prioritizes open discussions about the products we oversee, allowing Americans to make informed health choices,” the spokesperson conveyed.

Pat Ausem, vice president of the Partnership to End Addiction, mentioned that what surprised her most was how narrowly the votes were split (8-6, 7-5).

According to the FDA scientists, there was no substantial evidence backing the approval, lacking clinical data to prove safety or efficacy. It also seems the committee consists of several new advisors who have a vested interest in peptide products. Kennedy, leading the MAHA movement, has previously mentioned in a podcast how much he supports peptides.

Katherine Ebeling, a nurse and author, regarded the peptide vote as a significant step for Secretary of Health Kennedy and the MAHA movement, making way for pharmacies to dispense popular peptide prescriptions.

However, some experts, like Orsem, have raised alarms about the increasingly popular yet unregulated self-administration of peptides. Many are turning to forums like Reddit or wellness influencers for guidance instead of consulting medical professionals.

There’s an evident decline in trust in traditional medicine, fueled by a wellness industry promoting a DIY approach. Influencers often share discount codes, blurring the lines between authentic recommendations and paid advertisements. Some promotions may violate FTC and FDA regulations, with penalties in play for undisclosed sponsorships.

With over 80 FDA-approved peptides already used in treatments like insulin and skin care, the wave of unapproved peptides is concerning, especially given how easily accessible they are through international distributors, sometimes priced as low as $5 per vial.

Recent reports from Chainalysis indicate that cryptocurrency transactions to gray market peptide vendors saw a dramatic rise in early 2026, tallying $27 million—a 150% jump from the previous quarter.

Orsem highlighted a potential danger, as some peptide manufacturers have ties to substances like fentanyl. She pointed out how social media trends create a convenient pipeline for minors, with influencers becoming trusted sources rather than healthcare professionals.

Ebeling elaborated that the peptide vote made by the committee was merely a recommendation, as no compounds received FDA approval that week. Although the agency typically aligns with the advisory committee’s vote, there have been instances where it diverged.

Such changes necessitate formal notice and commentary procedures, a process the agency has expedited, completing it in about an hour. This reinforces the ongoing complexity surrounding peptide approval and regulation.